Profusa, Inc.

NVAC, a healthcare-focused special purpose acquisition company, filed an 8-K with the SEC on November 10, 2022, disclosing developments related to its proposed business combination with Profusa, Inc., a San Francisco-based life sciences company known for its implantable biosensor technology designed for continuous physiological monitoring. The SPAC, which went public in 2021, targets the medical technology and digital health sector. The 8-K filing, recorded under accession number 0001213900-22-071254, reflects a transaction that was subject to customary regulatory and shareholder conditions at the time of filing. Visit SpacDesk to sign up for full deal timelines, filing histories, and sponsor data on NVAC and hundreds of other active SPAC transactions.